502.47
price down icon3.12%   -16.19
after-market アフターアワーズ: 512.51 10.04 +2.00%
loading
前日終値:
$518.66
開ける:
$518.22
24時間の取引高:
331.05K
Relative Volume:
0.95
時価総額:
$11.58B
収益:
$958.40M
当期純損益:
$-288.28M
株価収益率:
-39.06
EPS:
-12.8641
ネットキャッシュフロー:
$-193.02M
1週間 パフォーマンス:
-2.75%
1か月 パフォーマンス:
-8.12%
6か月 パフォーマンス:
+5.59%
1年 パフォーマンス:
+64.00%
1日の値動き範囲:
Value
$497.23
$522.01
1週間の範囲:
Value
$497.23
$524.80
52週間の値動き範囲:
Value
$265.00
$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
名前
Madrigal Pharmaceuticals Inc
Name
セクター
Healthcare (1106)
Name
電話
404-380-9263
Name
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
職員
915
Name
Twitter
@MadrigalPharma
Name
次回の収益日
2026-05-06
Name
最新のSEC提出書
Name
MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
MDGL icon
MDGL
Madrigal Pharmaceuticals Inc
502.47 11.96B 958.40M -288.28M -193.02M -12.86
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 109.34B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 74.35B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 50.44B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 39.78B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.02B 5.36B 287.73M 924.18M 2.5229

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 開始されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-05 アップグレード Cantor Fitzgerald Neutral → Overweight
2025-11-03 アップグレード BofA Securities Underperform → Neutral
2025-10-15 開始されました Truist Buy
2025-09-04 再開されました H.C. Wainwright Buy
2025-02-28 アップグレード B. Riley Securities Neutral → Buy
2025-02-27 繰り返されました H.C. Wainwright Buy
2024-06-28 開始されました Cantor Fitzgerald Neutral
2024-06-11 開始されました Wolfe Research Outperform
2024-04-22 開始されました BofA Securities Underperform
2024-03-15 アップグレード B. Riley Securities Sell → Neutral
2024-03-06 開始されました Citigroup Buy
2024-02-26 ダウングレード B. Riley Securities Neutral → Sell
2022-12-20 繰り返されました Oppenheimer Outperform
2022-12-19 繰り返されました H.C. Wainwright Buy
2022-12-19 繰り返されました Piper Sandler Overweight
2022-12-19 アップグレード Raymond James Underperform → Mkt Perform
2022-07-08 ダウングレード B. Riley Securities Buy → Neutral
2021-10-07 開始されました Jefferies Buy
2021-08-06 アップグレード BMO Capital Markets Market Perform → Outperform
2021-05-20 再開されました Goldman Buy
2020-11-24 再開されました Evercore ISI Outperform
2020-11-06 繰り返されました H.C. Wainwright Buy
2020-07-31 開始されました Piper Sandler Overweight
2020-06-05 開始されました BMO Capital Markets Market Perform
2020-05-05 開始されました Chardan Capital Markets Buy
2020-01-30 開始されました Canaccord Genuity Buy
2020-01-09 アップグレード UBS Neutral → Buy
2019-11-07 繰り返されました H.C. Wainwright Buy
2019-06-25 開始されました Stifel Hold
2019-06-10 アップグレード B. Riley FBR Neutral → Buy
2019-02-28 繰り返されました H.C. Wainwright Buy
2019-02-22 開始されました SVB Leerink Outperform
2019-01-23 開始されました UBS Neutral
2018-12-14 開始されました Wolfe Research Outperform
2018-12-12 開始されました B. Riley FBR Neutral
2018-11-19 ダウングレード Raymond James Mkt Perform → Underperform
2018-11-16 アップグレード Evercore ISI In-line → Outperform
2018-09-04 開始されました Citigroup Buy
2018-08-06 ダウングレード Goldman Buy → Neutral
2018-06-28 開始されました Raymond James Mkt Perform
すべてを表示

Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース

pulisher
01:29 AM

Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH - MedCity News

01:29 AM
pulisher
01:21 AM

Madrigal earnings on deck: Can Rezdiffra sustain blockbuster pace? - Investing.com

01:21 AM
pulisher
11:55 AM

Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology

11:55 AM
pulisher
09:24 AM

Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace

09:24 AM
pulisher
08:45 AM

Madrigal Pharmaceuticals Inc announces exclusive global license for Aro-Pnpla3 from Arrowhead - marketscreener.com

08:45 AM
pulisher
08:39 AM

Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Australia

08:39 AM
pulisher
08:09 AM

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline - The Manila Times

08:09 AM
pulisher
08:00 AM

After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug - Stock Titan

08:00 AM
pulisher
May 04, 2026

Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget

May 04, 2026
pulisher
May 03, 2026

3 Biotech Stocks to Watch for Respectable Growth Beyond AI - AOL.com

May 03, 2026
pulisher
May 03, 2026

(MDGL) Movement as an Input in Quant Signal Sets - Stock Traders Daily

May 03, 2026
pulisher
May 03, 2026

MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN

May 03, 2026
pulisher
May 02, 2026

MSN Money - MSN

May 02, 2026
pulisher
May 01, 2026

Madrigal upgraded at Cantor on Rezdiffra launch - MSN

May 01, 2026
pulisher
May 01, 2026

MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill

May 01, 2026
pulisher
Apr 30, 2026

BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $536 - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Madrigal Expands Resmetirom Reach With New Post-Transplant MASH Trial - TipRanks

Apr 30, 2026
pulisher
Apr 29, 2026

Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Finance Canada

Apr 29, 2026
pulisher
Apr 29, 2026

Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Apr 29, 2026
pulisher
Apr 29, 2026

3,876 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Moody Aldrich Partners LLC - MarketBeat

Apr 29, 2026
pulisher
Apr 29, 2026

Madrigal to Report Q1 2026 Results May 6, Host Webcast - MyChesCo

Apr 29, 2026
pulisher
Apr 28, 2026

Madrigal Pharmaceuticals Reclassifies Board Ahead of 2026 Meeting - TipRanks

Apr 28, 2026
pulisher
Apr 28, 2026

Madrigal Pharmaceuticals | 8-K: Current report - Moomoo

Apr 28, 2026
pulisher
Apr 28, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) reshapes Board classes ahead of 2026 meeting - Stock Titan

Apr 28, 2026
pulisher
Apr 28, 2026

Madrigal Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo

Apr 28, 2026
pulisher
Apr 28, 2026

[ARS] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan

Apr 28, 2026
pulisher
Apr 28, 2026

Madrigal Pharmaceuticals | DEFA14A: Others - Moomoo

Apr 28, 2026
pulisher
Apr 28, 2026

Madrigal Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo

Apr 28, 2026
pulisher
Apr 28, 2026

Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish (NASDAQ:MDGL) - Seeking Alpha

Apr 28, 2026
pulisher
Apr 28, 2026

Madrigal Grants Equity Awards to 12 New Employees - MyChesCo

Apr 28, 2026
pulisher
Apr 28, 2026

Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. - BioPharma Dive

Apr 28, 2026
pulisher
Apr 28, 2026

Pictet Asset Management Holding SA Sells 9,847 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Apr 28, 2026
pulisher
Apr 27, 2026

Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

M&T Bank Corp Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Apr 27, 2026
pulisher
Apr 27, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 31% Upside Potential in the Biotech Arena - DirectorsTalk Interviews

Apr 27, 2026
pulisher
Apr 27, 2026

Calamos Advisors LLC Boosts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Apr 27, 2026
pulisher
Apr 27, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 27, 2026
pulisher
Apr 26, 2026

Here are the most and least likely M&A targets in biotech, according to Truist - MSN

Apr 26, 2026
pulisher
Apr 26, 2026

Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Apr 26, 2026
pulisher
Apr 25, 2026

Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN

Apr 25, 2026
pulisher
Apr 25, 2026

Madrigal Pharmaceuticals - The Pharma Letter

Apr 25, 2026
pulisher
Apr 24, 2026

Lobbying Update: $380,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative

Apr 24, 2026
pulisher
Apr 24, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat

Apr 24, 2026

Madrigal Pharmaceuticals Inc (MDGL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):